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BIM mediates synergistic killing of B-cell acute
lymphoblastic leukemia cells by BCL-2 and MEK
inhibitors
K Korfi1, M Smith1, J Swan2, TCP Somervaille3, N Dhomen1 and R Marais*,1
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematological disease that kills ~ 50% of adult patients. With the
exception of some BCR-ABL1+ patients who benefit from tyrosine kinase inhibitors, there are no effective targeted therapies for
adult B-ALL patients and chemotherapy remains first-line therapy despite adverse side effects and poor efficacy. We show that,
although the MEK/ERK pathway is activated in B-ALL cells driven by different oncogenes, MEK inhibition does not suppress
B-ALL cell growth. However, MEK inhibition synergized with BCL-2/BCL-XL family inhibitors to suppress proliferation and induce
apoptosis in B-ALL cells. We show that this synergism is mediated by the pro-apoptotic factor BIM, which is dephosphorylated as
a result of MEK inhibition, allowing it to bind to and neutralize MCL-1, thereby enhancing BCL-2/BCL-XL inhibitor-induced cell
death. This cooperative effect is observed in B-ALL cells driven by a range of genetic abnormalities and therefore has significant
therapeutic potential.
Cell Death and Disease (2016) 7, e2177; doi:10.1038/cddis.2016.70; published online 7 April 2016
Acute lymphoblastic leukemia (ALL) is the most common
childhood cancer and the third most common adult leukemia.
Childhood ALL has good outcomeswith 5-year survival rates of
~ 90%, whereas prognosis in older patients (15–65 years;
~ 40%of cases) isworse, with ~50%of patients dying from their
disease. B-cell ALL (B-ALL) is the most common ALL (~70% of
cases), so this disease has a clear unmet clinical need.1,2 In
addition to age, B-ALL outcome and response to therapy is
determined by the genetic alterations that drive disease, with
the BCR-ABL1 and MLL rearrangement being associated with
particularly poor prognosis.3 Chemotherapy remains first-line
treatment in childhood and adult B-ALL1 and is combined with
tyrosine kinase inhibitors (TKIs) in BCR-ABL1+ cases,4 but
despite increased survival from intensive chemotherapy regi-
mens, short- and long-term adverse effects are major draw-
backs and the presence of chemoresistant subclones limits
responses.5 Thus there is an urgent need for novel targeted
therapies with improved efficacy and reduced toxicity.
The RAS/RAF/MEK/ERK pathway regulates proliferation in
haematological malignancies and is activated by mutant RAS
or RAF, activated receptor tyrosine kinases such as KIT and
FLT3, chromosomal translocations such as BCR-ABL1 or
ETV6-PDGFR, or chemotherapeutic agents.6 Mutations in
NRAS, KRAS, and the protein phosphatase PTPN11 are
associated not only with relapse and poorer outcomes in
childhood leukemia but also with increased sensitivity to MEK
inhibitors (MEKi).7,8 Critically, this pathway regulates survival
and apoptosis through ERK-mediated phosphorylation of
apoptotic effectors such as BAD and BIM or transcriptional
regulation of BCL-2 family genes.6,9,10
In this study, we investigated how MEK/ERK signaling
regulates B-ALL proliferation and survival. We found that
inhibition of this pathway primed B-ALL cells for death by
BCL-2/BCL-XL inhibitors (BCL-2i) through a mechanism
dependent on the pro-apoptotic protein BIM. Thus we reveal
a synergistic interaction between two pro-survival pathways
that has therapeutic potential in a range of B-ALL subtypes.
Results
MEK inhibition does not block B-ALL cell growth. The
MEK/ERK pathway is activated downstream of driver
oncogenes such as BCR-ABL1 and NRAS,6 and accordingly,
we observed different levels of MEK/ERK pathway activation
not only in six B-ALL cell lines expressing BCR-ABL1+ or
NRASG12D but also in four cell lines driven by other
oncoproteins, including ETV6-PDGFRB, ETV6-RUNX1, and
MLL-AF4, except RS4;11 cells, which demonstrated no MEK/
ERK pathway activity (Figures 1a and b; Supplementary
Figures S1a and b; Supplementary Table S1). We therefore
investigated this pathway in B-ALL cell proliferation and
survival. Surprisingly, even profound pathway inhibition by
the small-molecule MEKi trametinib (Figure 1c) did not inhibit
B-ALL cell growth (Figure 1d; Supplementary Figures S1c
and d; Supplementary Table S2) and induced only modest
apoptosis (Figure 1e).
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BCL-2 and BCL-XL attenuate the effects of MEK inhibi-
tion in B-ALL cells. Thus the MEK/ERK pathway was active
in B-ALL cells but was not required for survival, so to
investigate the mechanisms underlying these cells’ intrinsic
resistance to MEKi, we examined BIM and BAD, because
ERK phosphorylates these pro-apoptotic proteins, inhibiting
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their binding to the pro-survival BCL-2 family members and
promoting cell survival.9,10 Trametinib did not block BAD
phosphorylation on serine 75 (S75) in B-ALL cells (Supple-
mentary Figure S2a), did not change BAD binding to
BCL-2 or BCL-XL, and did not induce BAD binding to a third
pro-survival protein, MCL-1 (Supplementary Figure S2b). In
contrast, trametinib induced robust BIM dephosphorylation
on S69 (Figure 1f), and although this did not affect BIM
binding to BCL-2, it significantly increased BIM binding to
MCL-1 in 697, BV173R, and SUP-B15 cells and to BCL-XL in
BV173R and SUP-B15 cells (Figures 1g and h).
We were intrigued that, despite these changes, MEK
inhibition did not induce profound apoptosis but noted that,
compared with normal CD34+ hematopoietic cells, BCL2
and BCLX (BCL2L1) were significantly upregulated in B-ALL
cells (Figure 2a). Accordingly, BCL-2 depletion significantly
reduced B-ALL cell survival, and BCL-XL depletion had a
modest effect (Figure 2b). More importantly, trametinib
cooperated with BCL-2 or BCL-XL depletion to further
suppress viability in these cells (Figure 2b).
MEKi and BCL-2i cooperate to induce B-ALL cell death.
The data above implicated BCL-2 and BCL-XL in intrinsic
resistance to MEKi, so we tested whether BCL-2i cooperated
with MEKi to suppress B-ALL cell viability. UMI-77, a selective
MCL-1 inhibitor did not reduce B-ALL cell viability either alone
or in combination with trametinib (Supplementary Table S3;
Supplementary Figure S3a). AT-101, which binds to BCL-2
and BCL-XL at 300–400 nM, also failed to reduce B-ALL cell
viability alone or in combination with trametinib (Supplemen-
tary Table S3; Supplementary Figure S3b). Similarly, sabu-
toclax, which binds to BCL-2 and BCL-XL at ~ 300 nM
reduced viability modestly by itself but failed to cooperate
with trametinib to kill the cells (Supplementary Table S3;
Supplementary Figure S3c).
In contrast, ABT-263,11 which binds to BCL-2 at 1 nM and
BCL-XL at 0.5 nM (Supplementary Table S3), not only inhi-
bited the growth of all three cell lines by itself but also
synergized with trametinib to further inhibit cell growth
(Figures 2c and d). Similarly, ABT-199,12 which binds to
BCL-2 at 0.01 nM and BCL-XL at 48 nM (Supplementary
Table S3), inhibited cell growth alone, and it cooperated with
trametinib to further reduce cell viability (Figure 2c). Note that
trametinib/ABT-263 and trametinib/ABT-199 combinationswere
more effective at reducing cell viability than the TKI nilotinib in
BCR-ABL1+ cells (Figure 2c). Furthermore, the loss of cell
viability with ABT-263 and ABT-199 was linked to increased
apoptosis, and these drugs cooperated with trametinib to
significantly increase apoptosis in these cells (Supplementary
Figure S4a). The death induced by the trametinib/ABT-263
combination was accompanied by loss of mitochondrial
membrane potential, demonstrating that apoptosis was mito-
chondrially mediated (Supplementary Figure S4b). We con-
clude that trametinib cooperated with the potent BCL-2i
ABT-199 and ABT-263 to induce B-ALL cell death.
BIM mediates synergistic killing of B-ALL cells by MEKi
and BCL-2i. We extended our findings to other B-ALL cell
lines and found that ABT-263 reduced viability of these cells
alone and synergized with trametinib to further suppress
viability of BV173, SUP-B15R, DOHH2, NALM6, REH, and
SEM cells (Figures 3a and b; Supplementary Figure S5;
Supplementary Table S4), and we observed similar results
with the ABT-199/trametinib combination (Supplementary
Figures S6a–d; Supplementary Table S4). Overall, the
trametinib/ABT-263 combination was more effective than
single agents in 9/11 lines and the trametinib/ABT-199
combination was more effective than single agents in 6/11
lines, so we were intrigued that the combinations did not
synergize to inhibit the growth of RS4;11 and SD1 cells
(Figure 3c; Supplementary Figures S6c and e). As shown
above, the MEK/ERK pathway is not active in RS4;11 cells
(Supplementary Figures S1a and b) and this is a prerequisite
for the cooperation between MEKi and BCL2i. However,
SD1 cells presented high levels of MEK/ERK activity
(Figure 1a) but intriguingly did not express BIM (Figures 3d
and e) and BIM re-expression was sufficient to kill these cells
(Figure 3f). This implicated BIM in the synergistic killing of
B-ALL cells by trametinib and ABT-263, and accordingly, we
show that when BIM was depleted, trametinib no longer
synergized with ABT-263 to kill BV173R or 697 cells
(Figures 3g and h; Supplementary Figures S7a and b).
These data showed that BIMmediated the synergistic killing
of B-ALL cells by MEKi and BCL-2i, so we investigated the
mechanism. Our data above showed that trametinib increased
BIM binding to MCL-1 (Figures 1g and h), and we found that
ABT-263 alone or in combination with trametinib further
increased BIM binding to MCL-1 (Figures 3i and j; Supple-
mentary Figures S7c and d). Moreover, we observed
increased BIM levels in the presence of trametinib alone or
in combination with ABT-263 (Figure 3k; Supplementary
Figure S7e), which could be due to the increased stability
of the dephosphorylated form.10 Importantly, the sensitivity
of B-ALL cells to ABT-263 was negatively correlated with
Figure 1 Trametinib primes B-ALL cells to apoptosis through BIM dephosphorylation. (a and b) Western blottings showing phospho-MEK (ppMEK), total MEK (MEK1/2),
phospho-ERK (ppERK), total ERK (ERK1/2), and α-tubulin (loading control) in five BCR-ABL1+ B-ALL cell lines (a) and six BCR-ABL1− cell lines (b). The dotted line indicates
where discontinuous sections of blots were joined. (c) Western blottings showing ppERK and ERK1/2 (loading control) in B-ALL cells treated with trametinib (40 nM) at the
indicated times. (d) Dose–response curves for trametinib (72 h) treatment of 697, BV173R, and SUP-B15 B-ALL cells. Cell viability (%) is relative to dimethyl sulfoxide (DMSO)
control and A375 (BRAFV600E melanoma) cells provide a positive control for sensitive cells. (e) Graphs represent apoptotic cells (%) after treatment with DMSO (control)
or trametinib (40nM) at the indicated times. (f) Western blottings showing phospho-S69-BIM (pBIM) and total BIM (BIMEL) in BIM immunoprecipitates from 697, BV173R, and
SUP-B15 cells treated with trametinib (40 nM) for the times indicated. (g) Western blottings showing BIM, BCL-2, BCL-XL, MCL-1, and α-tubulin (loading control) in cell lysates
and BIM co-IPs from 697, BV173R, and SUP-B15 cells treated with DMSO (control; D) or trametinib (40 nM; T) for 24 h. (h) Graphs represent normalized quantification of
BIM co-IPs from triplicate experiments for samples shown in panel (g). Error bars in panels (d, e, and h): S.E.M. *Po0.05; **Po0.01
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endogenous levels of BIM and MCL-1 (Supplementary
Figures S8a and b), and when MCL-1 was depleted,
ABT-263 strongly inhibited B-ALL cell proliferation even in
the absence of trametinib (Supplementary Figures S8c and d).
This suggested that the increase in BIM protein and its
interaction with MCL-1 in the presence of both MEKi and
BCL-2i, neutralized MCL-1, a mechanism that explains the
synergistic effect observed between trametinib and ABT-263
in these cells.
MEKi and BCL-2i cooperate to kill primary B-ALL cells
and to delay the onset of B-ALL in vivo. Next we investi-
gated whether MEKi and BCL-2i combinations could also
kill freshly isolated cells from B-ALL patients (Supplemen-
tary Table S5, Figure 4a). At clinically achievable doses,
trametinib and ABT-263 reduced the viability of undifferen-
tiated CD34+/CD19hi cells purified from peripheral blood
mononucleated cells of five B-ALL patients, but more
importantly, these agents cooperated to further reduce cell
Figure 2 MEKi and BCL-2i synergize to kill B-ALL cells. (a) Scatter dot plot showing mRNA expression for BCL2, BCLX (BCL2L1), and MCL1 relative to housekeeping gene
control in the 11 B-ALL cell lines (Supplementary Table S1) and normal primary CD34+ cells. Error bars: mean with 95% confidence intervals. **Po0.01; NS, not significant.
(b) Graphs showing cell viability (%) in 697, BV173R, and SUP-B15 cells transfected with control siRNA (siCtl), BCL-2 (siBCL-2), or BCL-XL (siBCL-XL) siRNAs and treated with
dimethyl sulfoxide (DMSO; control; D) or trametinib (40nM; T) for 72 h. The western blottings below the graphs show knockdown efficacy. (c) Graphs showing cell viability after
72 h at 200 nM (697, BV173R cells) or 40 nM (SUP-B15 cells) ABT-263 or ABT-199 with or without 40 nM trametinib as indicated. BCR-ABL1+ cells were also treated with
nilotinib (1 μM). Results are relative cell viability (%) to DMSO controls. Error bars in panels (b and c): S.E.M. *Po0.05; **Po0.01. (d) Isobolograms for trametinib/ABT-263
combinations in 697, BV173R, and SUP-B15 cells. Crosses on x and y axes indicate the IC50 values for each compound. Blue dots show the concentrations of the single drugs
that lead to 50% inhibition in cell viability for the given combination ratios. Combination indices (CI) for the combination drug concentrations in panel (c) are also indicated
(CIo1= synergism)
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viability in these cells (Figure 4a). As a control, we showed
that trametinib and ABT-263 had a negligible effect on
normal CD34+ cell viability from two non-ALL individuals
(Figure 4b), showing that this combination specifically
targeted the leukemic cells while sparing normal hemato-
poietic cells.
Finally, 697 cells were inoculated into non-obese diabetic
scid gamma (NSG) mice, and the mice were treated
with trametinib, ABT-263, or the combination for 3 weeks.
Mice were killed at the onset of leukemia, manifested by
ill health. We observed a small increase in survival
with trametinib and a more substantial survival advantage
with ABT-263, but critically these compounds cooperated
to give a significant if modest increase in survival com-
pared with the single-agent treatments (Figure 4c). Further-
more, trametinib and ABT-263 alone reduced the bone
marrow leukemic cell burden by ~ 40% (Po0.05) compared
with controls, but together, these agents reduced the leukemic
cell burden in the bone marrow by ~ 60% (Po0.001;
Figure 4d).
Discussion
This study demonstrates that MEKi plus BCL-2i is a promising
drug combination in B-ALL cells. Recent studies suggested
that only leukemias with mutations in RAS could benefit
from MEKi therapy,7,13 but we showed that this pathway
was activated in B-ALL cell lines driven by a range of
genetic aberrations. We showed that inhibition of ERK
resulted in dephosphorylation of the pro-apoptotic protein
BIMEL, an important regulator of apoptosis in normal and
malignant B cells, and a tumor suppressor in B-cell
malignancies.14 It has been reported that BIM phosphorylation
by ERK1/2 increased cell survival through reduced BIM
binding to pro-survival proteins, including BCL-XL and MCL-1,
and by increased BIM degradation.10,15 Accordingly, we
showed that trametinib caused BIM dephosphorylation,
resulting in upregulation of BIM protein and its binding to
MCL-1, consistent with a recent study in chronic lymphocytic
leukemia (CLL) showing that CLL cells were MCL-1-
dependent and phosphorylated BIM was unable to interact
with MCL-1 to induce apoptosis.16
However, despite priming B-ALL cells for apoptosis,
trametinib only modestly affected their viability, suggesting
that BIM dephosphorylation alone was insufficient to over-
come pro-survival signals. Accordingly, the pro-survival genes
BCL2 and BCLX were elevated in B-ALL cells compared with
normal CD34+ cells. Upregulation of antiapoptotic proteins
has been reported in some hematological malignancies,17,18
stimulating the development of potent BCL-2i.11,12 Importantly,
it was reported that BCL-2 overexpression in lymphoid malig-
nancies inhibited apoptosis through BIM sequestration19,20
and that BCL-2i induced apoptosis by disrupting the BCL-2/
BIM complex.
Here we showed that B-ALL cells demonstrate a range
of sensitivities to ABT-199 and ABT-263, although complete
loss of cell viability was not seen at clinically achievable
doses. However, the cells could be killed when BCL-2i were
combined with MEKi or when MCL-1 was depleted. Thus,
in accordance with previous studies,21,22 we showed that
intrinsic resistance of B-ALL cells to BCL-2i was mediated by
MCL-1 and that the pro-survival effects of MCL-1 were
overcome by BIM, which is phosphorylated and inactivated
downstreamofMEK/ERK. Previous studies showed that MEKi
and BCL-2i cooperated to inhibit the growth of KRAS and
BRAF mutant solid tumors.23,24 In those cases, MEK
appeared to be the primary growth inhibitor, and BCL-2i
enhanced the effect. However, we showed here that MEKi had
a modest effect in B-ALL cells, but MEK inhibition sensitized
the cells to BCL-2i through a MEK/ERK signaling-dependent
mechanism mediated by BIM.
Thus we posit that the mechanism by which MEKi and
BCL-2i cooperated to kill B-ALL cells was that MEK inhibition
caused BIM dephosphorylation and upregulation at the
protein level, allowing BIM to bind to and neutralize MCL-1,
removing one survival signal. The concomitant inhibition of
BCL-2 and BCL-XL removed the other survival signals,
leading to cell death. Importantly, this cooperative effect
occurred in B-ALL cells driven by a range of genetic
abnormalities. We validated our findings in primary CD34+
CD19hi B-ALL cells at clinically achievable doses for both
drugs while demonstrating that the combination spared
normal CD34+ cells. Additionally, as the effect was mediated
by BIM, the expression of this protein could serve as a
convenient biomarker to stratify patients for this combination
therapy. Our findings provide further insights into B-ALL cell
biology and survival mechanisms and identify MEK and
BCL-2/BCL-XL as targets that could be exploited for effective
management of this disease.
Materials and Methods
Cell culture. For cell lines and their driver oncogenes, see Supplementary Table
S1. BV173, BV173R, 697, and SD1 cells were cultured in RPMI 1640 medium
supplemented with 20% fetal bovine serum (FBS) and 1% penicillin/streptomycin
(Life Technologies, Paisley, UK). DOHH2, NALM6, REH, and SEM cells were
cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/
streptomycin. SUP-B15 and SUP-B15R cells were cultured in McCoy’s 5A medium
(Life Technologies) supplemented with 20% FBS and 1% penicillin/streptomycin.
RS4;11 cells cultured in α-MEM medium (Life Technologies) supplemented with
10% FBS and 1% penicillin/streptomycin.
Primary CD34+ ALL and normal cells were cultured in IMDM medium (Life
Technologies) supplemented with 25% BIT (bovine serum albumin/insulin/transferrin;
StemCell Technologies, Vancouver, BC, Canada), L-glutamine, penicillin/streptomy-
cin, and 125 μM 2-mercaptoethanol (Life Technologies). ALL CD34+ cells were
cultured in the presence of FLT3-ligand (100 ng/ml), IL-7 (100 ng/ml), and SCF
(100 ng/ml), as described.25 Normal CD34+ cells were cultured in a five growth
factor cocktail containing FLT3-ligand (100 ng/ml), G-CSF (20 ng/ml), IL-3 (20 ng/ml),
IL-6 (20 ng/ml), and SCF (100 ng/ml) (all growth factors are from PeproTech, Rocky
Hill, NJ, USA).
Primary cells from patient samples. Peripheral blood from B-ALL
patients was collected at diagnosis following informed consent and ethical
approval from the scientific sub-committee of the Manchester Cancer Research
Centre Tissue Biobank (07/H1003/161+5) and in compliance with the ethical
and legal framework of the Declaration of Helsinki and the UK’s Human
Tissue Act, 2004. Normal mobilized CD34+ cells surplus to requirements were from
patients undergoing chemotherapy and autologous transplantation, and their use
was authorized by the Salford and Trafford Research Ethics Committee (08/
H1004/114) for samples collected since 2006 and following written informed consent
of donors. Mononuclear cells were isolated from peripheral blood by Ficoll
separation. CD34+ cell enrichment was by AutoMACS magnetic column separation
(Miltenyi Biotec, Bergisch Gladbach, Germany) using the CD34 Human Microbead
Kits (Miltenyi Biotec). CD34+ cells from B-ALL samples were 490% CD19+ by
flow cytometry (anti-human CD19 PE, eBioscience, San Diego, CA, USA). For
BCL-2/MEK inhibitor cooperation in B-ALL
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clinical information and genetic abnormalities in patient samples, see
Supplementary Table S5.
Reagents (inhibitors, siRNAs, and plasmids). Stock solutions (10 mM)
of trametinib, ABT-199, ABT-263, AT-101, sabutoclax, and UMI-77 (Selleckchem,
Houston, TX, USA) were prepared in DMSO and stored at − 80 °C. Appropriate
concentrations of each drug were prepared in DMSO prior to use. Cell lines were
transfected with siRNAs to BCL-2 (ON-TARGETplus Human BCL2 SMARTpool;
Dharmacon, Lafayette, CO, USA), BCL-XL (Hs_BCL2L1_2, QIAGEN, Hilden,
Germany), MCL-1 (Hs_MCL1_6, QIAGEN), BIM (Hs_BCL2L11_5, QIAGEN),
and BAD (Hs_BAD_3, QIAGEN) using 4D-Nucleofector system (Lonza, Basel,
Switzerland). AllStars Negative Control siRNA (QIAGEN) was the negative control.
The BIM-GFP expression plasmid was constructed by cloning the human BIMEL
cDNA (BCL2L11-001, ENST00000393256) into a pMCEF vector and moving the
BCL-2/MEK inhibitor cooperation in B-ALL
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BamHI and AgeI restriction fragment into the pEGFP-N1 vector. The plasmid was
transfected into SD1 cells using 4D-Nucleofector system (Lonza) and GFP+ cells
were sorted by flow cytometry after 48 h.
Immunoprecipitation and immunoblot assays. Cell lysates were
prepared using cell lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
Na2EDTA, 1mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1mM Na3VO4, 1 μg/ml leupeptin; Cell Signaling, Danvers,
MA, USA) with protease inhibitor cocktail and phosphatase inhibitor cocktail 3
(Sigma Aldrich, St. Louis, MO, USA). For co-immunoprecipitation (co-IP), cell
extracts were prepared in CHAPS lysis buffer (20 mM Tris-HCl (pH 7.5), 137 mM
NaCl, 1% CHAPS, 1 mM EDTA, 1mM EGTA, 5 mM MgCl2, protease inhibitor
cocktail, and phosphatase inhibitor cocktail 3) as described.26 Protein extracts were
immunoprecipitated with anti-BIM (C34C5; Cell Signaling) and anti-BAD (C-7; Santa
Cruz Biotechnology, Dallas, TX, USA) at 4 °C for 2 h. Immunoprecipitates were
captured by 50 μl of protein G-agarose beads in CHAPS lysis buffer (Roche,
Basel, Switzerland) at 4 °C for 3 h. Immunoprecipitates were recovered by
centrifugation, washed three times in CHAPS buffer, and eluted in boiling NuPAGE
LDS Sample Buffer and NuPAGE Sample Reducing Agent (Life Technologies).
Immunoprecipitates and cell lysates (40 μg of protein) were separated by
SDS-PAGE on NuPAGE Bis-Tris gels (Life Technologies). Immunoblots were
performed with antibodies from Cell Signaling (BAX, BCL-XL, BIM, phosphoSer69-
BIM, ERK1/2, MEK1/2, and phosphoSer217/Ser221-MEK), Santa Cruz (BCL-2
and BAD), Sigma-Aldrich (MCL-1, diphosphorylated ERK1/2, and α-tubulin), and
Abcam (Cambridge, UK; phosphoSer112-BAD), probed by fluorescence secondary
antibodies (Li-Cor, Lincoln, NE, USA) and analyzed on an Odyssey CLx infrared
imaging system (Li-Cor). Densitometry analyses of western blotting bands were
Figure 4 Trametinib and ABT-263 cooperate to kill primary B-ALL cells and delay the onset of leukemia in vivo. (a) Graphs showing viability of purified CD34+ B-ALL cells from
five patients 72 h after treatment with trametinib (40 nM) and/or ABT-263 (40 nM). (b) Graphs showing viability of normal CD34+ cells purified from two non-leukemic individuals
72 h after treatment with trametinib (40 nM) and/or ABT-263 (40 nM). Results are shown as percentage of cell viability relative to dimethyl sulfoxide control. Error bars: S.E.M.
(c) Kaplan–Meier survival curves showing leukemia-free survival of mice inoculated with 697 cells and treated with vehicle, trametinib (0.15 mg/Kg), ABT-263 (100 mg/Kg), or
trametinib (0.15 mg/Kg) plus ABT-263 (100 mg/Kg) for 3 weeks. (d) Scatter dot plot showing human CD19+ cells (%) measured by flow cytometry in the bone marrow of the mice
at death in each treatment arm shown in panel (c). Error bars: mean with 95% confidence intervals. *Po0.05; **Po0.01; NS, not significant
Figure 3 BIM mediates the synergism between trametinib and ABT-263. (a) Graphs showing cell viability after 72 h at 200 nM ABT-263 with or without 40 nM trametinib in
BCR-ABL1+ cells (BV173, SUP-B15R) as indicated. Nilotinib is used at 1 μM. (b) Graphs showing cell viability after 72 h at 200 nM (DOHH2, REH, SEM cells) or 1 μM (NALM6
cells) ABT-263 with or without 40 nM trametinib as indicated. (c) Graph represents viability of SD1 cells after 72 h at 1 μM ABT-263 with or without 40 nM trametinib as indicated.
Nilotinib is used at 1 μM. (d) Scatter dot plot showing BIM (BCL2L11) mRNA expression relative to housekeeping gene control in the 11 B-ALL cell lines. Error bar: mean with
95% confidence intervals. (e) Western blottings show BIM and α-tubulin (loading control) expression in the B-ALL cells. (f) Graph displays (%) cell viability of SD1 cells 72 h after
BIM-GFP transfection relative to GFP-transfected cells. The analysis was performed on cells selected for GFP expression by fluorescence-activated cell sorting. (g) Graphs
showing BV173R cell viability 72 h after transfection with control siRNA (siCtl), siRNA BIM (siBIM), or siRNA BAD (siBAD) siRNAs and treated with trametinib (40 nM) and/or
ABT-263 (200 nM). (h) Western blottings showing the level of pro-survival and antisurvival proteins in BV173R cells after transfection with siCtl, siBIM, or siBAD. (i) Western
blottings showing BIM, BCL-2, BCL-XL, MCL-1, and α-tubulin (loading control) in BV173R cell lysates or BIM co-IPs 24 h after treatment with trametinib (40 nM) and/or ABT-263
(200 nM). (j) Graphs represent normalized quantification of BIM co-IPs from triplicate experiments for samples shown in panel (h). (k) Graph shows normalized quantification of
total BIM in lysates from triplicate experiments for samples shown in panel (h). Results in panels (a, b, c, and g) are relative cell viability (%) to dimethyl sulfoxide (DMSO) control.
Error bars in panels (a, b, c, f, g, j, and k): S.E.M. *Po0.05; **Po0.01; NS, not significant
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performed on Image Studio Lite (Li-Cor). For BIM co-IP assays, normalized IP fold
changes were calculated from band densitometries for BIM and its interacting
proteins as follows:
Interacting proteintreatment
BIMtreatmentCBIMDMSO
C
Interacting proteinDMSO
BIMDMSOCBIMDMSO
:
Cell viability assays. Cell lines were seeded at 1 × 104–2 × 104 cells/well and
primary cells were seeded at 5 × 104 cells/well in 96-well plates and treated with
DMSO (control) or small-molecule inhibitors for 72 h at 37 °C and 5% CO2. Cell
proliferation and viability was measured by a methanethiosulfonate-based assay
(CellTiter 96 Aqueous One Solution; Promega, Madison, WI, USA). Results were
reported as the percentage of viability for cell lines or viability for primary cells
relative to DMSO controls, and the S.E.M. was calculated from triplicates. The
combined effect of trametinib and ABT-263 in fixed ratio combinations was quantified
by the Chou–Talalay method.27
Apoptosis assays. The percentage of apoptotic cells in the presence or
absence of small-molecule inhibitors was determined using 7-AAD (7-aminoacti-
nomycin D) and PE annexin V probes (BD Biosciences, Franklin Lakes, NJ, USA)
on a BD Accuri C6 flow cytometer (BD Biosciences). Results were reported as the
average percentage of annexin V+ cells, and the S.E.M. was calculated from
triplicates.
Mitochondrial membrane potential was determined 24 h posttreatment with
DMSO or small-molecule inhibitors using a TMRE (tetramethylrhodamine,
ethyl ester) Mitochondrial Membrane Potential Assay Kit (Abcam) according to
the manufacturer’s instructions. Cells treated with FCCP (carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone), an ionophore uncoupler of oxidative phos-
phorylation, were used as positive control for the loss of mitochondrial membrane
potential.
Real-time PCR (RT-PCR). RNA was extracted from cells by the RNeasy Mini
Kit (QIAGEN), and cDNA was synthesized using the High-Capacity RNA-to-cDNA
Kit (Life Technologies), according to the manufacturers' instructions. For
mRNA expression levels, RT-PCR assays were performed using human TaqMan
probes for BCL2 (Hs00608023_m1), BCL2L1 (BCLX) (Hs00236329_m1), BCL2L11
(BIM) (Hs00708019_s1), MCL1 (Hs01050896_m1), and human GAPDH endo-
genous control probe (4352934E, Life Technologies). Reactions were performed in
triplicate on an ABI PRISM 7900HT platform (Life Technologies), and results were
reported as the expression levels relative to the housekeeping gene in the
same cells.
Generation of xenografts and in vivo drug treatments. All
procedures involving animals, carried out under license PPL-70/7701, were
performed in accordance with ARRIVE guidelines and National Home Office
regulations under the Animals (Scientific Procedures) Act 1986 and reviewed by the
Cancer Research UK Manchester Institute’s Animal Welfare and Ethics Review
Body (AWERB). 697 cell-derived xeongrafts were generated by intravenous
injection of 1 × 104 697 cells into the tail vein of 6–8-week-old female NSG mice
(Charles River Laboratories, Wilmington, MA, USA). Seven days postinjection, mice
were randomized into four treatment groups of similar total average body weight
(n= 10 mice per group) and vehicle (10% ethanol, 30% polyethylene glycol (Sigma-
Aldrich), and 60% Phosal 50 PG (Lipoid, Ludwigshafen, Germany)), trametinib
(0.15 mg/Kg), ABT-263 (100 mg/Kg), or the combination were administered daily by
oral gavage for 3 weeks, as described for ABT-263’s in vivo dosing protocol.11 For
combination therapy, trametinib was administered 1–2 h before ABT-263. Mice were
killed upon demonstrating ill health (loss of body weight, lack of vitality, hind limb
paralysis), and bone marrow cells were extracted for flow cytometric analysis of
human CD19+ cells.
Statistics. Data are presented as means± S.E.M., and P-values were
calculated using unpaired Student’s t-test for comparisons involving two groups
and one-way ANOVA with Holm–Sidak multiple comparison correction tests for
comparisons involving more than two groups. Furthermore, two-way ANOVA with
Holm–Sidak multiple comparisons correction tests were used for comparisons of
fold changes in BIM co-IP assays in four treatment conditions. Survival curves for
in vivo treatments were compared using Logrank (Mantel–Cox test). P-values
o0.05 are considered statistically significant.
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